FORM 5
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
[ ] Form 3 Holdings Reported
[ ] Form 4 Transactions Reported
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

                                                                                  

OMB APPROVAL
OMB Number: 3235-0362
Expires: January 31, 2008
Estimated average burden
hours per response...
1.0
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Kern Tracy A

2. Issuer Name and Ticker or Trading Symbol

CHAD THERAPEUTICS INC [CTU]

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chief Financial Officer

(Last)          (First)          (Middle)

21622 PLUMMER ST

3. Statement for Issuer's Fiscal Year Ended (MM/DD/YYYY)
3/31/2008 
(Street)

CHATSWORTH, CA 91311

(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form Filed by One Reporting Person
___ Form Filed by More than One Reporting Person


Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Amount (A) or (D) Price
Common Shares   4/30/2007   4/30/2007   A   127   A $1.86   9816   I   401(k)  
Common Shares   5/30/2007   5/30/2007   A   114   A $2.07   9816   I   401(k)  
Common Shares   6/30/2007   6/30/2007   A   150   A $1.58   9816   I   401(k)  
Common Shares   8/1/2007   8/1/2007   A   206   A $1.14   9816   I   401(k)  
Common Shares   8/31/2007   8/31/2007   A   243   A $0.97   9816   I   401(k)  
Common Shares   9/1/2007   9/1/2007   A   2   A $1.03   9816   I   401(k)  
Common Shares   10/1/2007   10/1/2007   A   294   A $0.80   9816   I   401(k)  
Common Shares   10/31/2007   10/31/2007   A   322   A $0.73   9816   I   401(k)  
Common Shares   11/30/2007   11/30/2007   A   366   A $0.44   9816   I   401(k)  
Common Shares   12/3/2007   12/3/2007   A   21   A $0.44   9816   I   401(k)  
Common Shares   12/26/2007   12/26/2007   A   547   A $0.31   9816   I   401(k)  
Common Shares   1/4/2008   1/4/2008   A   4   A $0.44   9816   I   401(k)  
Common Shares   2/1/2008   2/1/2008   A   308   A $0.55   9816   I   401(k)  
Common Shares   2/8/2008   2/8/2008   D   16   D $0.40   9816   I   401(k)  
Common Shares   3/8/2008   3/8/2008   A   439   A $0.38   9816   I   401(k)  
Common Shares   3/28/2008   3/8/2008   A   286   A $0.46   9816   I   401(k)  

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YYYY)
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned at End of Issuer's Fiscal Year
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
(A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Kern Tracy A
21622 PLUMMER ST
CHATSWORTH, CA 91311


Chief Financial Officer

Signatures
/s/ Tracy A. Kern 5/6/2008
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Chad Therapeutics (AMEX:CTU)
過去 株価チャート
から 11 2024 まで 12 2024 Chad Therapeuticsのチャートをもっと見るにはこちらをクリック
Chad Therapeutics (AMEX:CTU)
過去 株価チャート
から 12 2023 まで 12 2024 Chad Therapeuticsのチャートをもっと見るにはこちらをクリック